User:Padraig Doolan/sandbox

Archport Ltd. was a bioprocessing start-up company created in 1998 to provide contract production and development services for the biopharmaceutical industry. In 2006, it was acquired by CU Chemie Uetikon and was relaunched as BioUETIKON in 2008.

Background
In 1998, the National Cell & Tissue Culture Centre (NCTCC), Dublin City University (DCU) launched a spin-off bioprocessing start-up company, Archport Ltd. to provide contract production and development services for the biopharmaceutical industry. The company generated 25-30 jobs on campus over a 15-year period and maintained some research activity on campus, employing scientists and supporting PhD students consistently over the following 28 years.



Services
Archport's range of services included GMP compliant animal cell culture and purification of active biopharmaceutical ingredients for clinical trials or market ready drugs, such as recombinant proteins, cell therapy products and monoclonal antibodies. It also provided the scale-up of mammal or insect cell cultures, purification processes and joint R&D services.

BioUETIKON
In September 2006, DCU announced that Archport Ltd., has been acquired by CU Chemie Uetikon, a division of the Swiss-based CPH Chemie and Papier Holdings Group, with a major investment programme planned to create up to 30 high tech jobs. CU Chemie Uetikon took an 80 per cent share of Archport, while DCU retained a 20 per cent holding. CU Chemie Uetikon’s objective was to build on its already-established purpose-built biopharmaceutical laboratories on the DCU campus by providing significant investment in new plant and staff for an expansion programme.

The new service-oriented bioprocessing company, now named BioUETIKON, was formally launched in April 2008. The company offers GMP-compliant mammalian cell cultures and downstream processing for development or manufacture of active pharmaceutical ingredients (APIs). Archport Ltd. (and its partner Institute the National Institute for Cellular Biotechnology) was visited by (later US Secretary of State and 2016 Presidential Candidate) Senator Hillary Clinton on Thursday, March 28, 2002